Related Experiment Video
Updated: Feb 6, 2026

Imaging of Estrogen Receptor-α in Rat Pial Arterioles using a Digital Immunofluorescent Microscope
Published on: November 29, 2011
Clinical Potential of Estrogen and Progesterone Receptor Imaging
Hannah M Linden1, Lanell M Peterson1, Amy M Fowler2
1Department of Medical Oncology, Seattle Cancer Care Alliance, UWMC, 825 Eastlake Avenue East, Valley Building LV-200, Seattle, WA 98109-1023, USA.
Abstract:
Molecular imaging using 16α-[18F]fluoro-17β-estradiol (FES) and 18F-fluoro-furanyl-norprogesterone PET can assess in vivo function of steroid hormone receptors in breast cancer. These experimental agents have been tested in many single-center clinical trials and show promise to elucidate prognosis and predict endocrine therapy response. The current multicenter trial of FES-PET imaging will help bring this radiotracer closer to clinical use. There is tremendous potential for these tracers to advance drug development, enhance understanding of estrogen receptor-positive tumor biology, and personalize treatment.
Insights
Molecular imaging with 16α-[18F]fluoro-17β-estradiol (FES) and other PET tracers shows promise for breast cancer patient prognosis and treatment response. A multicenter trial is advancing FES-PET imaging toward clinical use.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Molecular imaging with 16α-[18F]fluoro-17β-estradiol (FES) and 18F-fluoro-furanyl-norprogesterone PET assesses in vivo steroid hormone receptor function in breast cancer.
- These experimental tracers have demonstrated potential in single-center trials for elucidating prognosis and predicting endocrine therapy response.
Purpose of the Study:
- To advance the clinical use of FES-PET imaging through a current multicenter trial.
- To explore the potential of these tracers in drug development, understanding estrogen receptor-positive tumor biology, and personalizing breast cancer treatment.
Main Methods:
- Utilizing 16α-[18F]fluoro-17β-estradiol (FES) and 18F-fluoro-furanyl-norprogesterone for Positron Emission Tomography (PET) imaging.
- Conducting a multicenter clinical trial to evaluate FES-PET imaging.
Main Results:
- FES-PET imaging shows promise in assessing in vivo function of steroid hormone receptors in breast cancer.
- Experimental agents have shown potential in predicting prognosis and endocrine therapy response in prior single-center trials.
Conclusions:
- The multicenter trial of FES-PET imaging is a significant step toward its clinical application.
- These molecular imaging tracers hold substantial potential for advancing breast cancer drug development, enhancing tumor biology understanding, and enabling personalized treatment strategies.
Related Concept Videos
Internal Receptors
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Receptor-mediated Endocytosis
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Standard Electrode Potentials
G-protein Coupled Receptors

